Fundraising Fox

64x Bio

YC S18

San Francisco, US · Founded 2017 · 25 employees · 11 known investors

Find your way into 64x Bio

550 people in our graph share verified history with the 64x Bio team — schools, employers, funds. One of them is your warm intro.

Karthik Ardhanareeswaranunlockedknows Lexi Rovner · together at Yale University (overlapped)
×4knows the team · via University of California, Berkeley
×4knows the team · via Harvard Medical School
×2knows the team · via Yale University
knows the team · via Wyss Institute for Biologically Inspired Engineering

64x develops infrastructure and manufacturing systems for next-generation medicines, focusing on genetic engineering, cell line development, and computational biology to enable scalability of advanced therapies.

Also known as 64-x · 64-X

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesGene TherapyMachine LearningUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (S18)

64x Bio was founded in 2017 by Lexi Rovner.

LRLexi Rovner
Lexi Rovnerin𝕏Co-founder & CEOLexi Rovner holds a PhD from Yale University and completed postdoctoral research in George Church's laboratory at Harvard Medical School. She is the CEO and co-founder of 64x Bio, a company that emerged from Harvard Medical School and the Wyss Institute.

Investors · 11

Fifty YearsSan Francisco · $250K – $2M
Future VenturesLos Altos · $1M – $10M
Lifeforce CapitalChevy Chase · $500K – $5M
Raptor GroupMiami Beachvia James J. Pallotta · inferred
Y CombinatorSan Francisco · $500K
Alix VenturesreportedSan Francisco · $100K – $500K
BoxGroupreportedNew York · $1M
First Round CapitalreportedSan Francisco · $1M – $7M
Northpond VenturesreportedBethesda · $100K – $5M
Refactor Capitalreported · 2 sourcesBurlingame · $1M – $2M
SV AngelreportedSan Francisco

Funding

SEC filings, press & company announcements

$55M disclosed across 1 round · 2022

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 2

by search overlap
Xenetic Biosciences4 shared keywordsXenetic Biosciences is a biopharmaceutical company developing immuno-oncology technologies for hard-to-treat cancers. Its DNase platform targets neutrophil extracellular traps (NETs) to improve existing treatments, with a systemic DNase program being advanced into the clinic as an adjunctive therapy for pancreatic carcinoma and other solid tumors.
Bio X Cell3 shared keywordsSupplier of 400+ research-use monoclonal antibodies serving academic, government, and commercial research customers worldwide.

Companies competing with 64x Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

64x Bio Launches LV Apex Suite, Expanding Its CellMap-Driven VectorSelect Platform Into Lentiviral Vector Productionbusinesswire.com · Jun 202664x Bio Launches AAV Apex Suite to Power the Next Generation of Gene Therapy Manufacturingbusinesswire.com · Jun 2025Pitch Deck: 64x Bio Raises $55 Million for Cell, Gene Therapy Tools. - Business Insiderbusinessinsider.com · Jan 202264x Bio Raises $55M To Advance Gene Therapy Platformnews.crunchbase.com · Jan 202264x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing - BioSpacebiospace.com · Jan 2022

Frequently asked questions

What does 64x Bio do?
64x develops infrastructure and manufacturing systems for next-generation medicines, focusing on genetic engineering, cell line development, and computational biology to enable scalability of advanced therapies.
Who founded 64x Bio?
64x Bio was founded by Lexi Rovner in 2017.
Who are 64x Bio's investors?
64x Bio's investors include Fifty Years, Future Ventures, Lifeforce Capital, Raptor Group, Y Combinator, Alix Ventures, BoxGroup, First Round Capital and 3 more.
How much funding has 64x Bio raised?
64x Bio has disclosed $55M raised across 1 round.
Where is 64x Bio headquartered?
64x Bio is headquartered in San Francisco, US.